Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 25;17(12):1583.
doi: 10.3390/ph17121583.

Berbamine Promotes the Repair of Lower Limb Muscle Damage in Chronic Limb-Threatening Ischemia by Inhibiting Local Inflammation and NF-κB Nuclear Translocation

Affiliations

Berbamine Promotes the Repair of Lower Limb Muscle Damage in Chronic Limb-Threatening Ischemia by Inhibiting Local Inflammation and NF-κB Nuclear Translocation

Lei Zheng et al. Pharmaceuticals (Basel). .

Abstract

Background/Objectives: Chronic Limb-Threatening Ischemia (CLTI) is a chronic limb ischemic disease caused by vascular lesions, characterized by pain, ulcers, and gangrene, which can be life-threatening in severe cases. The objective of this study is to explore whether Berbamine (BBM) can protect against and repair ischemic muscle tissue in the lower limbs; Methods: Using a mouse hindlimb ischemia (HLI) model, 36 C57BL6 mice were divided into sham, HLI, and HLI+BBM treatment groups. Results: Our findings indicate that BBM can restore motor function and muscle tissue pathology in mice, potentially by inhibiting the nuclear translocation of nuclear factor kappa-B (NF-κB), thereby alleviating tissue inflammation caused by chronic ischemia, reducing muscle cell apoptosis, inhibiting M1 macrophage polarization, and promoting angiogenesis. Conclusions: Our research suggests that BBM has the potential to protect against ischemic damage in lower limb muscle tissue, providing a new approach to the treatment of CLTI.

Keywords: apoptosis; berbamine; inflammation; limb ischemia; nuclear factor kappa-B.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
BBM enhances motor function and ameliorates muscle tissue pathology in mice with hindlimb ischemia (HLI). (a) Representative images of gastrocnemius muscles, measured by H&E staining (transverse section). (b) Quantification of the mean cross-sectional area of skeletal muscle HE staining, n = 8 per group. (c,d) Representative images of PAS staining and quantification of gastrocnemius muscles, transverse section, n = 8 per group. (e,f) Representative images of oil red O staining and quantification of gastrocnemius muscles, transverse section, n = 8 per group. (g,h) Representative images of Masson staining and quantification of gastrocnemius muscles, transverse section, n = 8 per group. (i) The endurance running distance of mice in each group over a fixed time, n = 8 per group. Data are expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 2
Figure 2
BBM promotes angiogenesis and skeletal muscle regeneration in the ischemic hind limbs of mice. (a,b) Representative immunohistochemistry images and quantification of CD31 in gastrocnemius muscles transverse sections, n = 8 per group. (c) The mRNA expression of VEGFA in gastrocnemius muscles examined by qPCR, n = 3 per group. (d,e) Representative immunofluorescence images and quantification of Edu in HUVECs, n = 3 per group. (f,g) Representative images and quantification of relative tube length and number of junctions in angiogenesis test, n = 3 per group. Data are expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 3
Figure 3
BBM inhibits M1 polarization of macrophages and inflammation in the ischemic hind limbs of mice. (a) The mRNA expression of iNOS, IL-6, IL-10, and Arg1 in gastrocnemius muscles examined by qPCR, n = 3 per group. (b,c) Representative immunofluorescence images and quantification of CD86 in gastrocnemius muscles transverse sections, n = 8 per group. (d,e) Representative immunofluorescence images and quantification of CD163 in gastrocnemius muscles transverse sections, n = 8 per group. (f) mRNA expression level of IL-1β and TNF-α in the gastrocnemius muscles of mice, detected by qPCR, n = 3 per group. Data are expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns: not significant.
Figure 4
Figure 4
BBM inhibits apoptosis induced by hind limb ischemia in mice. (a,b) Representative immunofluorescence images and quantification of Tunel staining in gastrocnemius muscles transverse sections, n = 8 per group. (c,d) Representative immunoblot bands and quantitative analysis of cleaved-Caspase-3 and cleaved-Parp1 in gastrocnemius muscles, n = 3 per group. Data are expressed as mean ± SEM. **** p < 0.0001.
Figure 5
Figure 5
Berbamine inhibits NF-κB nuclear translocation. (a,b) nuclear translocation was determined by immunofluorescence staining for p65 (red) and DAPI staining for DNA (blue), n = 8 per group. (c,d) Nuclear p65 protein expression in gastrocnemius muscles was analyzed by western blot, n = 3 per group. Data are expressed as mean ± SEM. **** p < 0.0001.

Similar articles

References

    1. Conte M.S., Bradbury A.W., Kolh P., White J.V., Dick F., Fitridge R., Mills J.L., Ricco J.B., Suresh K.R., Murad M.H., et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur. J. Vasc. Endovasc. Surg. 2019;58:S1–S109.e33. doi: 10.1016/j.ejvs.2019.05.006. - DOI - PMC - PubMed
    1. Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat. Rev. Cardiol. 2022;19:456–474. doi: 10.1038/s41569-021-00663-9. - DOI - PubMed
    1. Farber A., Menard M.T., Conte M.S., Kaufman J.A., Powell R.J., Choudhry N.K., Hamza T.H., Assmann S.F., Creager M.A., Cziraky M.J., et al. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N. Engl. J. Med. 2022;387:2305–2316. doi: 10.1056/NEJMoa2207899. - DOI - PubMed
    1. Furubeppu H., Ito T., Kakuuchi M., Yasuda T., Kamikokuryo C., Yamada S., Maruyama I., Kakihana Y. Differential Regulation of Damage-Associated Molecular Pattern Release in a Mouse Model of Skeletal Muscle Ischemia/Reperfusion Injury. Front. Immunol. 2021;12:628822. doi: 10.3389/fimmu.2021.628822. - DOI - PMC - PubMed
    1. Bihari A., Cepinskas G., Forbes T.L., Potter R.F., Lawendy A.R. Systemic application of carbon monoxide-releasing molecule 3 protects skeletal muscle from ischemia-reperfusion injury. J. Vasc. Surg. 2017;66:1864–1871. doi: 10.1016/j.jvs.2016.11.065. - DOI - PubMed

LinkOut - more resources